Investment in Cerba Vet and ANTAGENE to broaden and enhance access to diagnostics solutions in France and better serve more veterinary professionals and pets 
  

McLean, Virginia, USA (July 2, 2024) — Mars, Incorporated (“Mars”) today announced that it has completed its previously announced acquisition of Cerba HealthCare’s ownership stake in Cerba Vet and ANTAGENE. Cerba Vet and ANTAGENE now complement the diagnostics portfolio in Mars Petcare’s Science & Diagnostics division.  
 

Nefertiti Greene, President, Mars Science & Diagnostics, said: “We are excited to join forces with the teams from Cerba Vet and ANTAGENE. Cerba Vet and ANTAGENE complement Mars Science & Diagnostics, which includes a global veterinary diagnostics business, Antech, and leading cat and dog genetic testing business, Wisdom Panel. Together we will further the Mars Petcare Purpose: A BETTER WORLD FOR PETS.”  
 

Media Contacts   
Mars, Incorporated media inquiries:    
Kekst CNC  
James Lindsay 
James.lindsay@kekstcnc.com